No Data
Harbin Gloria Pharmaceuticals (002437.SZ): Buyback completed, with a cumulative repurchase of 1.42% of shares.
On March 14, Gelonghui reported that Harbin Gloria Pharmaceuticals (002437.SZ) announced that the actual buyback period was from March 10, 2025, to March 13, 2025. During this period, the company repurchased a total of 32,307,224 shares, accounting for 1.42% of the company's total equity, with a maximum Fill Price of 2.51 yuan/share, a minimum Fill Price of 2.44 yuan/share, and a total amount of funds used (excluding transaction costs) of 79.9941 million yuan. This buyback plan has been completed.
Overview of the restrictions and unlocks of A-shares on March 12.
According to the Zhito Finance APP, on March 12, a total of 1 listed company had its restricted shares unlocked, with a total market value of approximately 61.9667 million yuan. The specific conditions for the restricted share unlock today are as follows: Stock Name Stock Code Share Type Unlocked Share Quantity Harbin Gloria Pharmaceuticals 002437 Stock-based Incentive Restricted Circulation 28.9564 million.
Difficult to recover equity transfer funds. Harbin Gloria Pharmaceuticals' PD-1 "divestiture" lawsuit may face a second instance | Quick Reading of Announcement.
① After winning the first instance, Harbin Gloria Pharmaceuticals has further developments in the lawsuit regarding the separation of Innovative Drugs assets. ② The acquiring party, Puxing Puli, has filed an appeal, requesting a ruling that it is not required to pay any penalties to Harbin Gloria Pharmaceuticals.
Here's Why HARBIN GLORIA PHARMACEUTICALS (SZSE:002437) Can Manage Its Debt Responsibly
Yuheng Pharmaceutical: 2024 Annual Performance Forecast
Benign Growth For HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) Underpins Its Share Price
The Market Doesn't Like What It Sees From HARBIN GLORIA PHARMACEUTICALS Co., LTD's (SZSE:002437) Revenues Yet As Shares Tumble 27%
